SK17332002A3 - Purínové deriváty - Google Patents

Purínové deriváty Download PDF

Info

Publication number
SK17332002A3
SK17332002A3 SK1733-2002A SK17332002A SK17332002A3 SK 17332002 A3 SK17332002 A3 SK 17332002A3 SK 17332002 A SK17332002 A SK 17332002A SK 17332002 A3 SK17332002 A3 SK 17332002A3
Authority
SK
Slovakia
Prior art keywords
amino
formula
ethyl
alkyl
compound
Prior art date
Application number
SK1733-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Simon John Mantell
Sandra Marina Monaghan
Peter Thomas Stephenson
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of SK17332002A3 publication Critical patent/SK17332002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
SK1733-2002A 2000-06-27 2001-06-14 Purínové deriváty SK17332002A3 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0015727.1A GB0015727D0 (en) 2000-06-27 2000-06-27 Purine derivatives
PCT/IB2001/001064 WO2002000676A1 (fr) 2000-06-27 2001-06-14 Derives de purine

Publications (1)

Publication Number Publication Date
SK17332002A3 true SK17332002A3 (sk) 2004-03-02

Family

ID=9894500

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1733-2002A SK17332002A3 (sk) 2000-06-27 2001-06-14 Purínové deriváty

Country Status (43)

Country Link
EP (1) EP1296996B1 (fr)
JP (1) JP2004501929A (fr)
KR (1) KR20030036248A (fr)
CN (1) CN1432020A (fr)
AP (1) AP1372A (fr)
AR (1) AR028759A1 (fr)
AT (1) ATE267836T1 (fr)
AU (1) AU2001264164A1 (fr)
BG (1) BG107171A (fr)
BR (1) BR0111912A (fr)
CA (1) CA2412564C (fr)
CZ (1) CZ20023992A3 (fr)
DE (1) DE60103537T2 (fr)
DK (1) DK1296996T3 (fr)
DO (1) DOP2001000195A (fr)
EA (1) EA200201291A1 (fr)
EC (1) ECSP024396A (fr)
EE (1) EE200200712A (fr)
ES (1) ES2220775T3 (fr)
GB (1) GB0015727D0 (fr)
GT (1) GT200100119A (fr)
HR (1) HRP20020995A2 (fr)
HU (1) HUP0301389A3 (fr)
IL (1) IL152529A0 (fr)
IS (1) IS6580A (fr)
MA (1) MA26918A1 (fr)
MX (1) MXPA03000078A (fr)
NO (1) NO20025975D0 (fr)
NZ (1) NZ521867A (fr)
OA (1) OA12294A (fr)
PA (1) PA8521001A1 (fr)
PE (1) PE20020213A1 (fr)
PL (1) PL361384A1 (fr)
PT (1) PT1296996E (fr)
PY (1) PY0115244A (fr)
SI (1) SI1296996T1 (fr)
SK (1) SK17332002A3 (fr)
SV (1) SV2002000507A (fr)
TN (1) TNSN01096A1 (fr)
TR (1) TR200401622T4 (fr)
UY (1) UY26797A1 (fr)
WO (1) WO2002000676A1 (fr)
ZA (1) ZA200209557B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1421078B1 (fr) 2001-08-14 2006-09-27 Eli Lilly And Company Derives d'indole en tantqu'agonistes du recepteur beta-3 adrenergique pour le traitement du diabete type 2
SE0201980D0 (sv) * 2002-06-24 2002-06-24 Astrazeneca Ab Novel compounds
AU2003275257A1 (en) 2002-09-26 2004-04-19 Bristol-Myers Squibb Company N-substituted heterocyclic amines as modulators of chemokine receptor activity
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
CN101437526A (zh) * 2004-09-20 2009-05-20 伊诺泰克制药公司 嘌呤衍生物及其用法
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
EP2322525B1 (fr) * 2006-04-21 2013-09-18 Novartis AG Dérivés de purine comme agonistes des récepteurs de l'adénosine A2A
US7589076B2 (en) * 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
WO2008037477A1 (fr) 2006-09-29 2008-04-03 Novartis Ag PYRAZOLOPYRIMIDINES UTILISÉES COMME INHIBITEURS DES LIPIDES KINASES Pl3K
CN101522682A (zh) 2006-10-30 2009-09-02 诺瓦提斯公司 作为抗炎剂的杂环化合物
US7897737B2 (en) 2006-12-05 2011-03-01 Lasergen, Inc. 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing
MX2010007604A (es) 2008-01-11 2010-08-02 Novartis Ag Pirimidinas como inhibidores de cinasa.
KR101677772B1 (ko) 2008-06-11 2016-11-18 레이저젠, 인코퍼레이티드 뉴클레오타이드 및 뉴클레오사이드 그리고 시퀀싱에서의 이들의 이용 방법
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
PE20121148A1 (es) 2009-08-17 2012-09-07 Intellikine Llc Compuestos heterociclicos y usos de los mismos
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
WO2012116217A1 (fr) 2011-02-25 2012-08-30 Irm Llc Composés et compositions en tant qu'inhibiteurs de trk
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
CA2856803A1 (fr) 2011-11-23 2013-05-30 Intellikine, Llc Regimes de traitement ameliores utilisant des inhibiteurs de mtor
JP2015512425A (ja) 2012-04-03 2015-04-27 ノバルティス アーゲー チロシンキナーゼ阻害剤との組合せ製品及びそれらの使用
EP2968340A4 (fr) 2013-03-15 2016-08-10 Intellikine Llc Combinaison d'inhibiteurs de kinase et ses utilisations
WO2015084804A1 (fr) 2013-12-03 2015-06-11 Novartis Ag Combinaison d'un inhibiteur de mdm2 et d'un inhibiteur de braf, et leur utilisation
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
ES2831416T3 (es) 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
CN113194752A (zh) 2018-06-01 2021-07-30 康奈尔大学 Pi3k相关疾病或病症的组合疗法
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988003147A1 (fr) * 1986-10-31 1988-05-05 Warner-Lambert Company Adenosines a substitution n6 selectionees ayant une activite de liaison a2 selective
IL107101A0 (en) * 1992-09-30 1993-12-28 Merrell Dow Pharma 2-substituted adenosines with a-2 receptor affinity
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
JP2002500188A (ja) * 1998-01-08 2002-01-08 ザ・ユニバーシティ・オブ・バージニア・パテント・ファウンデーション Ａ２ａアデノシンレセプター作動因子
AU5879299A (en) * 1998-10-16 2000-05-08 Monaghan, Sandra Marina Adenine derivatives
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924363D0 (en) * 1999-10-14 1999-12-15 Pfizer Central Res Purine derivatives
GB9924361D0 (en) * 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
HUP0301389A2 (hu) 2003-08-28
CA2412564C (fr) 2007-10-02
GT200100119A (es) 2002-01-31
GB0015727D0 (en) 2000-08-16
PT1296996E (pt) 2004-08-31
EP1296996A1 (fr) 2003-04-02
TR200401622T4 (tr) 2004-08-23
PL361384A1 (pl) 2004-10-04
SI1296996T1 (en) 2004-10-31
AP1372A (en) 2005-02-21
ATE267836T1 (de) 2004-06-15
CA2412564A1 (fr) 2002-01-03
BG107171A (bg) 2003-07-31
IS6580A (is) 2002-10-10
ECSP024396A (es) 2003-02-06
NO20025975L (no) 2002-12-12
PE20020213A1 (es) 2002-03-19
BR0111912A (pt) 2003-05-13
EE200200712A (et) 2004-06-15
EA200201291A1 (ru) 2003-04-24
MXPA03000078A (es) 2003-08-19
OA12294A (en) 2003-11-14
NO20025975D0 (no) 2002-12-12
HRP20020995A2 (en) 2005-02-28
ES2220775T3 (es) 2004-12-16
DE60103537T2 (de) 2005-07-07
DK1296996T3 (da) 2004-08-16
DOP2001000195A (es) 2002-05-15
PA8521001A1 (es) 2002-04-25
CZ20023992A3 (cs) 2003-12-17
ZA200209557B (en) 2003-12-02
DE60103537D1 (de) 2004-07-01
MA26918A1 (fr) 2004-12-20
WO2002000676A1 (fr) 2002-01-03
AR028759A1 (es) 2003-05-21
KR20030036248A (ko) 2003-05-09
EP1296996B1 (fr) 2004-05-26
UY26797A1 (es) 2002-01-31
PY0115244A (es) 2003-11-03
HUP0301389A3 (en) 2005-02-28
IL152529A0 (en) 2003-05-29
TNSN01096A1 (fr) 2005-11-10
JP2004501929A (ja) 2004-01-22
SV2002000507A (es) 2002-07-03
AU2001264164A1 (en) 2002-01-08
NZ521867A (en) 2004-04-30
CN1432020A (zh) 2003-07-23

Similar Documents

Publication Publication Date Title
SK17332002A3 (sk) Purínové deriváty
AU2001260537B2 (en) 2-aminocarbonyl-9H-purine derivatives
CZ20021179A3 (cs) Purinové deriváty
AU764106B2 (en) Purine derivatives
SK4842002A3 (en) Purine derivatives
US6525032B2 (en) Purine derivatives
US6921753B2 (en) Purine derivatives
JP2002527524A (ja) アデニン誘導体
US6753322B2 (en) 2-aminocarbonyl-9H-purine derivatives
HK1089447B (en) A process for the preparation of 2-aminocarbonyl-9h-purine derivatives and the intermediates thereof